HUTCHMED (China) (HCM) vs Nurix Therapeutics (NRIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 131.2% versus a loss of 10.6%. Over five years, NRIX leads with a -21.2% price change compared with -55.8% for HCM. HUTCHMED (China) is the larger company by market cap ($2.48 billion vs $2.36 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | NRIX |
|---|---|---|
| Share price | $14.28 | $22.73 |
| Market cap | $2.48B | $2.36B |
| 1-day change | -2.19% | +0.58% |
| YTD return | +7.13% | +19.82% |
| 1-year return | -10.64% | +131.23% |
| 5-year return | -55.79% | -21.16% |
| P/E ratio (TTM) | 142.80 | — |
| Forward P/E | 55.09 | — |
| EPS (TTM) | $0.10 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.33 | $28.23 |
| 52-week low | $9.77 | $9.00 |
| Distance from 52-week high | -12.55% | -19.48% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +54.13% | +49.27% |
| Average volume | 67.86K | 1.27M |
| Shares outstanding | 173.81M | 103.78M |
| Employees | 1,790 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed HCM by 141.9 percentage points over the past year.
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
HCM vs NRIX FAQ
Which is bigger, HUTCHMED (China) or Nurix Therapeutics?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.48B compared with $2.36B for Nurix Therapeutics (NRIX).
Which stock has performed better over the past year, HCM or NRIX?
NRIX returned +131.23% over the past 12 months, compared with -10.64% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and Nurix Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.